Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03719664
Recruitment Status : Recruiting
First Posted : October 25, 2018
Last Update Posted : January 29, 2019
Sponsor:
Information provided by (Responsible Party):
Frontier Biotechnologies Inc.

Brief Summary:
The study is an adaptive, phase 2, multicenter, three-part study to establish the dosage, safety and antiviral activity of combination therapy with albuvirtide (ABT) and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection.

Condition or disease Intervention/treatment Phase
HIV-1-infection Drug: Albuvirtide Drug: 3BNC117 Drug: Baseline ART Phase 2

Detailed Description:

This is a three-part, multicenter study that will enroll a total of 80 eligible, HIV-1 subjects who are virologically suppressed and stable on daily oral combination antiretroviral therapy. The study will be conducted in three parts.

Part 1 and Part 2 are the dose-ranging portions of the study. In Part 1, 30 eligible subjects will be randomized in a 1:1:1 ratio to receive 16 weeks of combination treatment with albuvirtide and 3BNC117 or continue on the existing ART regimen under one of the three cohorts as follows:

  • Cohort 1: albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
  • Cohort 2: albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
  • Control Arm 1: Subjects continuing on baseline ART

In Part 2 of the study, 20 eligible subjects will be randomized in a 1:1 ratio to receive 16 weeks of combination treatment with albuvirtide and 3BNC117 under one of the two cohorts as follows:

  • Cohort 3: albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
  • Cohort 4: albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks

Part 3 of this study will enroll an additional 30 subjects in a 2:1 ratio to receive up to 28 weeks of combination treatment with optimal dose of albuvirtide and 3BNC117 or continue on the existing ART regimen as follows:

  • Optimal Dose: albuvirtide and 3BNC11 every 2 or 4 weeks
  • Control Arm 2: Subjects continuing on baseline ART All consenting patients, in Cohort 1 and 2 (Part 1) and Cohort 3 and 4 (Part 2) of the study, will be shifted from daily oral combination antiretroviral regimen to an intravenous infusion of ABT and 3BNC117. The total treatmentduration with the ABT and 3BNC117 combination regimen will be up to 16 weeks (for Part 1 and Part 2) or 28 weeks (for Part 3) with a two week overlap of the baseline oral antiretroviral regimen and the ABT-3BNC117 combination regimen at the beginning of the study treatment and at the end of the treatment phase in subjects who do not experience virologic rebound. During the two week overlap of baseline oral antiretrovirals and ABT-3BNC117 combination regimen at the beginning of the study treatment, subject will receive weekly doses of ABT and 3BNC117 as intravenous infusions. Beyond the overlap period, subjects in Cohort 1 will receive study treatments every two weeks and subjects in Cohort 2, 3, and 4 will receive study treatments every four weeks.

Study participants will be monitored for viral rebound every two weeks following initiation of ABT-3BNC117 combination and will re-initiate an oral antiretroviral regimen if virologic rebound is confirmed with plasma HIV-1 RNA levels above 200 copies/ml on two consecutive blood draws.

Pharmacokinetics of ABT and 3BNC117 will be assessed in this study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Three-part Study to Establish the Dosage, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects With HIV-1 Infection
Actual Study Start Date : December 17, 2018
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Cohort 1: albuvirtide & 3BNC117
albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
Drug: Albuvirtide
Intravenous infusion of Albuvirtide
Other Name: Fusion inhibitor

Drug: 3BNC117
Intravenous infusion of 3BNC117
Other Name: Monoclonal antibody

Experimental: Cohort 2: albuvirtide & 3BNC117
albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
Drug: Albuvirtide
Intravenous infusion of Albuvirtide
Other Name: Fusion inhibitor

Drug: 3BNC117
Intravenous infusion of 3BNC117
Other Name: Monoclonal antibody

Active Comparator: Control Arm 1: Baseline ART
Subjects continuing on baseline ART
Drug: Baseline ART
Subjects continuing on baseline ART
Other Name: ART

Experimental: Cohort 3: albuvirtide & 3BNC117
albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
Drug: Albuvirtide
Intravenous infusion of Albuvirtide
Other Name: Fusion inhibitor

Drug: 3BNC117
Intravenous infusion of 3BNC117
Other Name: Monoclonal antibody

Experimental: Cohort 4: albuvirtide & 3BNC117
albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks
Drug: Albuvirtide
Intravenous infusion of Albuvirtide
Other Name: Fusion inhibitor

Drug: 3BNC117
Intravenous infusion of 3BNC117
Other Name: Monoclonal antibody

Experimental: Optimal Dose: albuvirtide & 3BNC117
albuvirtide and 3BNC117 every 2 or 4 weeks
Drug: Albuvirtide
Intravenous infusion of Albuvirtide
Other Name: Fusion inhibitor

Drug: 3BNC117
Intravenous infusion of 3BNC117
Other Name: Monoclonal antibody

Active Comparator: Control Arm 2: Baseline ART
Subjects continuing on baseline ART
Drug: Baseline ART
Subjects continuing on baseline ART
Other Name: ART




Primary Outcome Measures :
  1. Proportion of participants with HIV-1 RNA < 50 copies/mL at the end of treatment phase in Part 3 of the study. [ Time Frame: 28 weeks in Part 3 ]

Secondary Outcome Measures :
  1. Proportion of participants with HIV-1 RNA < 50 copies/mL at the end of treatment phase in Part 1 of the study [ Time Frame: 16 weeks in Part 1 ]
  2. Proportion of participants with HIV-1 RNA < 50 copies/mL at the end of treatment phase in Part 2 of the study [ Time Frame: 16 weeks in Part 2 ]
  3. Time to virologic rebound after discontinuation of baseline ART regimen [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
    Note: Virologic rebound is defined as two consecutive HIV-1 RNA levels of > 200 copies/ml.

  4. Proportion of participants achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
  5. Time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
  6. Mean change in HIV-1 RNA, at each visit within the treatment phase [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
  7. Mean change in CD4 cell count, at each visit within the treatment phase [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
  8. Mean change in CD4:CD8 ratio, at each visit within the treatment phase [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
  9. Emergence of new resistance mutations to antiretroviral drugs as evaluated by GenoSure Archive or PhenoSense GT Assay [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
  10. Measurement of treatment adherence to the ABT and 3BNC117 combination regimen [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Potential subjects are required to meet all of the following criteria for enrollment into the study.

    1. HIV-1 seropositive;
    2. Males and females, age ≥18 years;
    3. Receiving oral combination antiretroviral therapy for last 24 weeks;
    4. No change in antiretroviral regimen within last 4 weeks prior to Screening Visit and in-between Screening Visit and First Treatment Visit with an exception that subjects on NNRTI-containing regimens will be allowed to switch to protease inhibitor- or integrase strand transferase inhibitor-based regimens and such change, if needed, should occur at least 4 weeks prior to cessation of oral antiretroviral therapy;
    5. Subject has two or more potential alternative antiretroviral drug options available;
    6. Plasma HIV-1 RNA <50 copies/mL at Screening Visit as determined by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR);
    7. No documented detectable viral loads (HIV-1 RNA > 50 copies/mL) within the last 24 weeks prior to Screening Visit. An exception for a recorded HIV-1 RNA "blip" (e.g., transient HIV-1 RNA <400 copies/mL) can be considered, although the preceding and following HIV-1 RNA measurements should be <50 copies/mL;
    8. CD4 cell count of >300 cells/mm3 at Screening Visit;
    9. Laboratory values at Screening:

      1. Absolute neutrophil count (ANC) ≥750/ mm3;
      2. Hemoglobin (Hb) ≥10.5 gm/dL (male) or ≥9.5 gm/dL (female);
      3. Platelets ≥75,000 /mm3;
      4. Serum alanine transaminase (SGPT/ALT) <1.25 x upper limit of normal (ULN);
      5. Serum aspartate transaminase (SGOT/AST) <1.25 x ULN;
      6. Serum total bilirubin within normal range; and
      7. Creatinine ≤1.5 x ULN.
    10. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator;
    11. Both male and female subjects and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized or who do not have sex with women). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug;
    12. Willing and able to participate in all aspects of the study, including use of intravenous medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Note: Subjects diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if in the opinion of site investigator these circumstances would not interfere with the subject's successful completion of the study requirements.

Exclusion Criteria:

  • Potential subjects meeting any of the following criteria will be excluded from enrollment.

    1. Any active infection or malignancy requiring acute therapy;
    2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg);
    3. Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV RNA assay at the time of screening;
    4. Grade 4 DAIDS laboratory abnormality;
    5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study;
    6. Unexplained fever or clinically significant illness within 1 week prior to the first study dose;
    7. Any vaccination within 2 weeks prior to the first study dose;
    8. Subjects weighing <35kg;
    9. History of anaphylaxis to any oral or parenteral drugs;
    10. Use of any fusion inhibitors and broadly neutralizing monoclonal antibody prior to the Screening Visit;
    11. Participation in an experimental drug trial(s) within 30 days of the Screening Visit;
    12. Any known allergy or antibodies to the study drug or excipients;
    13. Treatment with any of the following:

      1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit;
      2. Immunosuppressants or immunomodulating agents within 60 days prior to the screening visit; or
      3. Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:

        • Subjects on inhaled, nasal, or topical steroids will not be excluded.
    14. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03719664


Contacts
Layout table for location contacts
Contact: Cheng Yao, M.D. (+86)025-69648387 yaocheng@frontierbiotech.com
Contact: Panpan Zhu ppzhu@frontierbiotech.com

Locations
Layout table for location information
United States, California
ABT-3BNC117_201 Investigational Site Recruiting
Palm Springs, California, United States, 92262
ABT-3BNC117_201 Investigational Site Recruiting
San Francisco, California, United States, 94115
United States, Florida
ABT-3BNC117_201 Investigational Site Recruiting
Fort Pierce, Florida, United States, 34982
ABT-3BNC117_201 Investigational Site Recruiting
Hialeah, Florida, United States, 33016
ABT-3BNC117_201 Investigational Site Recruiting
Orlando, Florida, United States, 32803
United States, Georgia
ABT-3BNC117_201 Investigational Site Recruiting
Atlanta, Georgia, United States, 30312
United States, New York
ABT-3BNC117_201 Investigational Site Recruiting
New York, New York, United States, 10029
Sponsors and Collaborators
Frontier Biotechnologies Inc.
Investigators
Layout table for investigator information
Study Director: Frontier clinical team Frontier Biotechnologies Inc.

Layout table for additonal information
Responsible Party: Frontier Biotechnologies Inc.
ClinicalTrials.gov Identifier: NCT03719664     History of Changes
Other Study ID Numbers: ABT-3BNC117_201
First Posted: October 25, 2018    Key Record Dates
Last Update Posted: January 29, 2019
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Frontier Biotechnologies Inc.:
HIV-1
3BNC117
Albuvirtide
Broadly neutralizing antibody
Long-Acting HIV-1 Fusion Inhibitor

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Antibodies
Immunologic Factors
Physiological Effects of Drugs